Graft-Versus-Host Disease

Human clinical trials move forward with promising therapy for graft-verses-host disease

May 31, 2013

HSCI investigators have developed a better picture of why a recently discovered therapy for graft-versus-host disease (GVHD) is more effective than anything currently available to patients.

In 2011, human clinical trials showed that immune system signaling molecule interleukin 2 (IL-2) both improved GVHD symptoms in Read more about Human clinical trials move forward with promising therapy for graft-verses-host disease